financetom
Business
financetom
/
Business
/
Update: MDA Space Q1 Adjusted Profit Down by Almost a Third, Revenue Climbs; Provides Outlook; Down Over 5%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: MDA Space Q1 Adjusted Profit Down by Almost a Third, Revenue Climbs; Provides Outlook; Down Over 5%
May 9, 2024 11:43 AM

02:20 PM EDT, 05/09/2024 (MT Newswires) -- MDA Space (MDA.TO), a robotics and satellite company, on Thursday reported first-quarter adjusted earnings, excluding one-time items, of $18.1 million, or $0.15 per share, down 32% from $26.5 million, or $0.22, a year earlier.

Four out of five analysts polled by Capital IQ expected $0.15.

Revenue for the quarter ended March 31 was $209.1 million, up 3.6% from $201.9 million a year earlier. Analysts surveyed by Capital IQ expected $212.3 million.

Adjusted EBITDA for Q1 was $42 million, down from $48.9 million a year ago.

For the second quarter, the company is expecting revenue of $215 million to $225 million as it continues to execute on its backlog. Analysts polled by Capital IQ are expecting $232.1 million.

For fiscal 2024, MDA reaffirmed the outlook previously provided in its fourth-quarter 2023 earnings release and continues to expect full-year revenue of $950 million to $1.05 billion, representing growth of about 25% at the mid-point of guidance as compared with 2023 levels.

Analysts surveyed by Capital IQ are expecting $1.01 billion.

MDA expects revenue growth to accelerate in the second half of 2024 as it ramps up work volumes on several programs. Adjusted EBITDA for 2024 is expected to be $190 million to $210 million, representing about 19% to 20% adjusted EBITDA margin.

The company continues to expect capital expenditures of $210 million to $230 million in 2024, comprising mainly of growth investments to support CHORUS and the previously outlined growth initiatives across its three business areas.

MDA's shares were last seen down C$0.87 to C$14.02 on the Toronto Stock Exchange.

Price: 14.06, Change: -0.83, Percent Change: -5.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
British Airways changes schedule due to Rolls-Royce parts delays
British Airways changes schedule due to Rolls-Royce parts delays
Oct 11, 2024
(Reuters) - British Airways said on Friday it has made additional changes to its schedule due to delays in the delivery of engines and parts from Rolls-Royce, particularly the Trent 1000 engines fitted to its 787 aircraft. We've taken this action because we do not believe the issue will be solved quickly, a British Airways spokesperson said in an emailed...
CeriBell Shares Soar in Nasdaq Debut
CeriBell Shares Soar in Nasdaq Debut
Oct 11, 2024
01:33 PM EDT, 10/11/2024 (MT Newswires) -- CeriBell (CBLL) shares soared in recent Friday trading after the medical technology company made its debut on Nasdaq. The stock was trading up over 41% at $23.99 in afternoon trading after opening at $23.26. The company is offering about 10.6 million shares at $17 a share in the initial public offering that is...
CIBC's Week Ahead Market Call For Canada
CIBC's Week Ahead Market Call For Canada
Oct 11, 2024
01:45 PM EDT, 10/11/2024 (MT Newswires) -- CIBC's Ali Jaffery and Katherine Judge noted Tuesday's CPI data will be the final piece of major information that the Bank of Canada receives on the economy ahead of the October meeting. The CIBC duo said headline inflation is expected to dip below target and look even more muted excluding mortgage interest costs....
Pfizer Gets FDA Approval for Hemophilia A, B Treatment
Pfizer Gets FDA Approval for Hemophilia A, B Treatment
Oct 11, 2024
01:44 PM EDT, 10/11/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that the US Food and Drug Administration approved Hympavzi to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B without certain inhibitors. The drug is approved for adults and pediatric patients 12 years or older, according to the company. The approval...
Copyright 2023-2026 - www.financetom.com All Rights Reserved